Eptinezumab Boosts Good Days in Chronic Migraine Sufferers

Research Summary

A recent study published in the Journal of Headache and Pain highlights the real-world effectiveness of eptinezumab for chronic migraine sufferers. The research focused on three groups: those with psychiatric conditions, previous anti-CGRP therapy users, and individuals experiencing brain fog. Among 94 participants, 65% had psychiatric comorbidities, and 89% had prior subcutaneous anti-CGRP treatment. Eptinezumab increased the average number of "good days" by about 10 days per month across various subgroups. Notably, those with improved brain fog experienced an average 15-day increase, while those without improvement saw just 1 extra day. The findings suggest eptinezumab offers substantial benefits for chronic migraine patients.

Study Details

📄 Title: Real-world effectiveness of eptinezumab in chronic migraine-increase in good days in three subgroups: psychiatric comorbidities, prior subcutaneous anti-calcitonin gene-related peptide therapy, and migraine-associated brain fog.

👥 Research Team: Argoff C et al.

📚 Published In: J Headache Pain

📅 Publication Date: 2025 Nov 27

⚕️ Medical Disclaimer: This summary is generated automatically from recent migraine research. Always consult with healthcare professionals for medical advice.